PLEASE ANSWER SEPARETELY TO EACH STUDENT WITH DIRECTIONS GIVEN!!! 200 WORDS PER

ORDER YOUR PAPER AND GET QUALITY FOR YOUR MONEY

PLEASE ANSWER SEPARETELY TO EACH STUDENT WITH DIRECTIONS GIVEN!!! 200 WORDS PER EACH STUDENT AND 2 CITATIONS PER STUDENTPeer Responses: You are required to post 2 Peer Responses each week. Your Peer Response should be 200 words and should build upon the author’s first post. You should include at least 2 APA formatted reference/citation that differs from the source in your Original Post. it is not enough to agree or disagree with your peer. Any statement of opinion should be supported by factual data to bolster your point of view.AUTHOR ANIKA: While reviewing the 2020 and 2021 Diagnostics Years in Review document one of the first trends I noticed between the two years is that molecular diagnostic testing has increased in 2021. There was a compound annual growth rate of 7.7% between the two years, increasing from 0.96 to 1.03 patients per million (Aspinall, 2022). Molecular testing is experiencing an upward trend between 2020 to 2021 however it is still relatively low compared to previous years with a 17% decrease (Aspinall, 2022). From the year 2020 to 2021 there has been an increase in molecular tests due to public health concerns about COVID-19. The idea behind this increase was to increase access to testing and to detect early confirmation cases (Dinnes et al., 2021). By being able to detect early cases it would have the possibility of lowering the transmission rate of infectious disease. This is likely to cause an increase in molecular tests between 2020 and 2021 when it was previously experiencing a decreasing trend.Another trend that was noticed when reviewing these two years is the decreasing trend of the clinically available genomic tests. With an annual compound growth rate of 22.6%, genomic in 2020 (Aspinal, n.d.) Along with a 20.4% growth rate in 2021 for molecular tests (Aspinal, 2022). Molecular tests overall have seen a steady increase since at least 2014 (Aspinall, n.d.). In 2020 the number of the genomic test was roughly around 165,000 while in 2021 the test was rough 175,000 (Aspinall, 2022.). There is a link between genomic variants and health however because of the slow evolution of the relationship it is still changing due to the complex interaction (Bilkey et al., 2019). This could be a possible explanation for the initial slow growth of genomic testing throughout the diagnostic realm. One of the main issues that clinicians and the patients involved in genomic testing run into is utility issues like informed consent (Bilkey et al., 2019). The complex nature of the testing makes it difficult to specify and delineate its total uses and capabilities, especially when detailed in layman’s terms to patients.AUTHOR 2 JESSICA: There are several multi-year trends that appear in the Diagnostics Years in Review documents spanning from 2019 to 2021. One major trend that has largely overshadowed other diagnostic trends in the past three years is the COVID-19 pandemic, which will not be discussed in depth in this discussion post as most individuals are sufficiently familiar with these trends. Rather, major trends from the 2017 and 2019 Year in Review documents will be discussed as they are equally interesting but have been largely overshadowed by the more immediate concern of the global pandemic.One multi-year trend that is of import is the movement towards using molecular targets rather than organ of origin (or organ system) to determine the appropriate treatment modality (Aspinall, 2018). This shift in treatment has largely been the result of increased understanding of the mechanisms of cancer and oncogenesis (Rosas and Raez, 2020). A major milestone in this shift was seen on May 23, 2017, when the FDA approved a treatment specifically for treating cancers with either high microsatellite instability or high DNA mismatch repair deficiency (Aspinall, 2018).This shift towards treatments targeted at specific biomarkers and away from organ systems has opened the door for another important trend, the increasing popularity of the companion diagnostic (Aspinall, 2020). As an increasing number of targeted therapies are developed an equal number of companion diagnostics will need to be developed to ensure that patients are able to receive both diagnosis and treatments specific to the biomarkers that are causing their ailments (Aspinall, 2020). The number of biomarker specific treatments and the corresponding companion diagnostics is only expected to increase, providing greater opportunities for diagnostic companies, pharmaceutical companies, and improving patient care (Aspinall, 2020). These two closely related trends in diagnostics are part of a larger movement to gain a greater understanding of biomarkers and towards agnostic-type treatment, specifically in the case of cancer (Rosas et al., 2020).